Trial document

This trial has been registered retrospectively.
drksid header


Trial Description

start of 1:1-Block title


CONKO-005:Adjuvant Therapy in R0-resected Pancreatic Cancer Patients with Gemcitabine plus Erlotinib vs. Gemcitabine over 24 Weeks - a Prospective, Randomized Phase III Study

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Pancreatic cancer is a particularly aggressive tumor with a poor prognosis and surgical resection is the only approach with the possibility of curation. For women it is the 4th and for men the 5th cause of tumor-related death. In addition, there is a recurrence rate of approximately 80% within 5 years. In case of a resectable tumor the 5-year survival rates vary in between 15 - 25% and depend on the result of the resection.
Recent findings from our study group (Oettle 2007) showed that those patients who received postoperative chemotherapy with the gemcitabine had a significantly lower risk of recurrence than those without adjuvant chemotherapy.
Even patients with complete (R0) resection have a poor median survival of approximately 18 months.
The CONKO-005 trial will straightly target these R0-resected patients.
It has been repeatedly shown that up to 90% of pancreatic cancers overexpress EGFR.
For this reason the inhibition of EGFR with "small molecules " like erlotinib might be o special interest. CONKO 005 trial evaluates the combination of gemcitabin and the selective EGFR-tyrosine kinase inhibitor erlotinib in the adjuvant setting. It might help to find out if this treatment is able to further reduce the risk of tumor recurrence by destroying intraoperative remaine or disseminated tumor cells.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Erlotinib is an inhibitor of tyrosine kinase epidermal growth factor receptor (EGFR, HER-1).
HER1/EGFR is expressed on the surface of normal cells but also by tumor cells.
The anti-tumor activity of erlotinib is based on the inhibition of intracellular tyrosine kinase region of HER1, thus preventing the intercellular signal transduction.
In preclinical models, inhibition of HER1 / EGFR tyrosinkinase effects the arrest of growth and / or death of the cell.
Preclinical data show an additive effect with cytotoxic drugs such as cisplatin, doxorubicin, or paclitaxel.
In these combination studies no side effects were shown.
For erlotinib are also data available from several phase I, II and III trials. Since January 2007 erlotinib has been admitted to a dose of 100 mg / day p.o. in combination with gemcitabine in the first-line therapy of metastatic pancreatic cancer in Europe .
The admission is based on data from a randomized phase III trail with 569 patients, which had demonstrated a significant benefit in overall survival with this combination compared to gemcitabine alone (p= 0.038).
Futhermore in this study the combination of erlotinib and gemcitabine was well tolerated (Moore et al. 2007).

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?


end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:


end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00000247
  •   2010/03/04
  •   [---]*
  •   yes
  •   Approved
  •   ZS EK 11 521/07, Ethik-Kommission des Landes Berlin
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   U1111-1114-0833 
  •   2007-003813-15 
  •   4033532 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   C25 -  Malignant neoplasm of pancreas
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Arm A:
    Erlotinib 100 mg p.o. daily plus Gemcitabin 1000 mg/m² i.v. day 1, 8, 15. repetition day 29
    Duration: 6 cycles (24 weeks)
  •   Arm B:
    Gemcitabin 1000 mg/m² i.v. day 1, 8, 15. repetition day 29
end of 1:N-Block interventions
start of 1:1-Block design


  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Open (masking not used)
  •   [---]*
  •   Active control (effective treament of control group)
  •   Treatment
  •   Parallel
  •   III
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Relaps-free survival (RFS)

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Overall survival, Toxicity

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • [---]*
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   Actual
  •   2008/04/15
  •   450
  •   Multicenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Histological confirmed diagnosis of an adenocarcinoma of the pancreas, Standardised surgery for tumor resection, e. g. partial pancreatoduodenectomy (Kausch-Whipple), pylorus-sparing partial pancreatoduodenectomy (PPPD), pancreas leftresection.
Result of resection: R0, No previous neoadjuvant therapy (chemotherapy or radiation), Performance-Status according to Karnofsky-Scale > 60 %, Patient compliance and geographical situation allowing an adequate follow up, especially the willingness to visit the same center regulary for at least 2 years after surgery, Sufficient bone marrow capacity: WBC > 3.5 × 109 /l, platelets
> 100 x 109/l, haemoglobin > 8 g/dl, Written informed consent of the patient prioral any precedure in connection with the study, Male and female patients with an age of at least 18 years, Initiation of the adjuvant therapy as soon as possible postoperative.
Soonest 2 weeks after resection but not before completion of
the wound healing at latest in between 8 weeks after resection.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

Seriouses systemic disease (with life expectance < 6 months) according to estimation of the investigator, active infection > Grad 2 NCI-CTCAE v3.0, Known HIV infection, Serious systemic disease: Uncontrolled hypertension, ingestive heart failure NYHA III - IV, symptomatic coronary heart disease, uncontrolled
cardial arrhythmia > grade II, peripher arterial disease > stage IIb, International Normalized Ratio (INR) > 1.5, prolongation of the activated partial prothrombin time (aPTT) > 1.5 x UNL (upper normal limit),
transaminases > 3x UNL, Postoperative measurable tumorlesion, Pregnant or breast-feeding women. Women of child-bearing potential must have an negative pregnancy test performed 7 days prior to start
of the treatment, Sexually active males or females with child-bearing potential unwilling to practice sufficient contraception during the study and for 3 months
after end of the study medication., Known allergical reactions against the study drugs or the substances included therein, Patients undergoing dialysis, Interstitial pneumonia or symptomatic fibrosis of the lung, Need of immunosuppressive therapy (e. g. transplantation), Severe non-healing wounds, ulcers or bone fracturs, Participation in another experimental clinical trial within 4 weeks prior to entry into the study, Previous or ongoing narcotic drug, medication- or alcohol abuse, Patients which are not able to take in oral drugs, need parenteral nutrition,are known to have an insufficient gastrointestinal resorption or
suffer from acute stomac ulcer, Other primary malignancy in the patient's history (except for successfully treated basalioma or carcinoma in situ of the cervix uteri)

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


  • start of 1:1-Block address primary-sponsor
    • Charité-Universitätsmedizin Berlin
    • Augustenburger Platz 1
    • 13353  Berlin
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Charité - Universitätsmedizin Berlin CharitéCentrum für Tumormedizin Medizinische Klinik mit Schwerpunkt Hämatologie/ Onkologie
    • Ms.  Dr. med.  Marianne  Sinn 
    • Augustenburger Platz 1
    • 13353  Berlin
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Studiensekretariat Charité - Universitätsmedizin Berlin CharitéCentrum für Tumormedizin Medizinische Klinik m. S. Hämatologie und Onkologie
    • Ms.  Dr.  Marianne  Sinn 
    • Auustenburger Platz 1
    • 13353  Berlin
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Roche Pharma
    • Emil-Barell-Strasse 1/ Postfach 1270
    • 79630  Grenzach-Wyhlen
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting complete, follow-up continuing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.